Evaluation of recombinant E2 protein-based and whole-virus inactivated candidate vaccines against chikungunya virus

Vaccine

Volumn 30, Issue 43, 2012, Pages 6142-6149

  Kumar, Manish ^a   Sudeep, A B ^a   Arankalle, Vidya A ^a  

^a NATIONAL INSTITUTE OF VIROLOGY   (India)

Author keywords

Chikungunya recombinant E2 protein; Inactivated vaccines; Sterilizing immunity; Viral load

Indexed keywords

ALUMINUM POTASSIUM SULFATE; INACTIVATED VIRUS VACCINE; NEUTRALIZING ANTIBODY; PEPTIDES AND PROTEINS; PROTEIN CADB; PROTEIN MW; RECOMBINANT E2 PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS VACCINE;

ALPHAVIRUS INFECTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; BRAIN; CHIKUNGUNYA ALPHAVIRUS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; HUMORAL IMMUNITY; MOUSE; MUSCLE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SPLEEN; VACCINATION; VIRUS LOAD;

ADJUVANTS, IMMUNOLOGIC; ALPHAVIRUS INFECTIONS; ALUM COMPOUNDS; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CERCOPITHECUS AETHIOPS; CHIKUNGUNYA VIRUS; CROSS REACTIONS; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNITY, HUMORAL; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; RECOMBINANT PROTEINS; VACCINES, INACTIVATED; VACCINES, SYNTHETIC; VERO CELLS; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES;

EID: 84865729966     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.07.072     Document Type: Article

References (36)

1. Powers A.M., Logue C.H. Changing patterns of chikungunya virus: re-emergence of a zoonotic arbovirus. J Gen Virol 2007, 88:2363-2377.
2. Ross R.W. The Newala epidemic. III. The virus: isolation, pathogenic properties and relationship to the epidemic. J Hyg (Lond) 1956, 54:177-191.
3. Diallo M., Thonnon J., Traore-Lamizana M., Fontenille D. Vectors of Chikungunya virus in Senegal: current data and transmission cycles. Am J Trop Med Hyg 1999, 60:281-286.
4. Borgherini G., Poubeau P., Jossaume A., Gouix A., Cotte L., Michault A., et al. Persistent arthralgia associated with chikungunya virus: a study of 88 adult patients on Reunion Island. Clin Infect Dis 2008, 47:469-475.
5. Sissoko D., Malvy D., Ezzedine K., Renault P., Moscetti F., Ledrans M., et al. Post-epidemic Chikungunya disease on Reunion Island: course of rheumatic manifestations and associated factors over a 15-month period. PLoS Negl Trop Dis 2009, 3:e389.
6. Sarkar J.K., Chatterjee S.N., Chakravarti S.K., Mitra A.C. Chikungunya virus infection with haemorrhagic manifestations. Indian J Med Res 1965, 53:921-925.
7. Schuffenecker I., Iteman I., Michault A., Murri S., Frangeul L., Vaney M.C., et al. Genome microevolution of chikungunya viruses causing the Indian Ocean outbreak. PLoS Med 2006, 3:e263.
8. Pialoux G., Gaüzère B.A., Jauréguiberry S., Strobel M. Chikungunya, an epidemic arbovirosis. Lancet Infect Dis 2007, 7:319-327.
9. Lakshmi V., Neeraja M., Subbalaxmi M.V., Parida M.M., Dash P.K., Santhosh S.R., et al. Clinical features and molecular diagnosis of Chikungunya fever from South India. Clin Infect Dis 2008, 46:1436-1442.
10. Tandale B.V., Sathe P.S., Arankalle V.A., Wadia R.S., Kulkarni R., Shah S.V., et al. Systemic involvements and fatalities during Chikungunya epidemic in India, 2006. J Clin Virol 2009, 46:145-149.
11. Economopoulou A., Dominguez M., Helynck B., Sissoko D., Wichmann O., Quenel P., et al. Atypical chikungunya virus infections: clinical manifestations, mortality and risk factors for severe disease during the 2005-2006 outbreak on reunion. Epidemiol Infect 2009, 137:534-541.
12. Yergolkar P.N., Tandale B.V., Arankalle V.A., Sathe P.S., Sudeep A.B., Gandhe S.S., et al. Chikungunya outbreaks caused by African genotype, India. Emerg Infect Dis 2006, 12:1580-1583.
13. Cui J., Gao M., Ren X. Phylogeny and homologous recombination in Chikungunya viruses. Infect Genet Evol 2011, 11:1957-1963.
14. Harrison V.R., Eckels K.H., Bartellori P.J., Hampton C. Production and evaluation of a formalin-killed Chikungunya vaccine. J Immunol 1971, 107:643-647.
15. Levitt N.H., Ramsburg H.H., Hasty S.E., Repik P.M., Cole F.E., Lupton H.W. Development of an attenuated strain of chikungunya virus for use in vaccine production. Vaccine 1986, 4:157-162.
16. Edelman R., Tacket C.O., Wasserman S.S., Bodison S.A., Perry J.G., Mangiafico J.A. Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218. Am J Trop Med Hyg 2000, 62:681-685.
17. Plante K., Wang E., Partidos C.D., Weger J., Gorchakov R., Tsetsarkin K., et al. Novel chikungunya vaccine candidate with an IRES-based attenuation and host range alteration mechanism. PLoS Pathog 2011, 7:e1002142.
18. Muthumani K., Lankaraman K.M., Laddy D.J., Sundaram S.G., Chung C.W., Sako E., et al. Immunogenicity of novel consensus-based DNA vaccines against chikungunya virus. Vaccine 2008, 26:5128-5134.
19. Mallilankaraman K., Shedlock D.J., Bao H., Kawalekar O.U., Fagone P., Ramanathan A.A., et al. A DNA vaccine against Chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates. PLoS Negl Trop Dis 2011, 5:e928.
20. Wang D., Suhrbier A., Penn-Nicholson A., Woraratanadharm J., Gardner J., Luo M., et al. A complex adenovirus vaccine against chikungunya virus provides complete protection against viraemia and arthritis. Vaccine 2011, 29:2803-2809.
21. Wang E., Volkova E., Adams A.P., Forrester N., Xiao S.Y., Frolov I., et al. Chimeric alphavirus vaccine candidates for chikungunya. Vaccine 2008, 26:5030-5039.
22. Akahata W., Yang Z.Y., Andersen H., Sun S., Holdaway H.A., Kong W.P., et al. A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection. Nat Med 2010, 16:334-338.
23. Reed J.L., Muench H. A simple method of estimating fifty percent endpoints. Am J Hyg 1938, 27:493-497.
24. Jadi R.S., Sudeep A.B., Barde P.V., Arankalle V.A., Mishra A.C. Development of an inactivated candidate vaccine against Chandipura virus (Rhabdoviridae: Vesiculovirus). Vaccine 2011, 29:4613-4617.
25. Patil D.R., Hundekar S.L., Arankalle V.A. Expression profile of immune response genes during acute myopathy induced by chikungunya virus in a mouse model. Microbes Infect 2011, Dec 30 [Epub ahead of print].
26. Shrivastava S., Lole K.S., Tripathy A.S., Shaligram U.S., Arankalle V.A. Dvelopment of candidate combination vaccine for hepatitis E and hepatitis B: a liposome encapsulation approach. Vaccine 2009, 27:6582-6588.
27. Saravanabalaji S., Tripathy A.S., Dhoot R.R., Chadha M.S., Kakrani A.L., Arankalle V.A. Viral load, antibody titres and recombinant open reading frame 2 protein-induced Th1/Th2 cytokines and cellular immune responses in self-limiting and fulminant hepatitis E. Intervirology 2009, 52:78-85.
28. Guy B. The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol. 2007, 5:505-517.
29. Gupte G.M., Arankalle V.A. Evaluation of the immunogenicity of liposome encapsulated HVR1 and NS3 regions of genotype 3 HCV, either singly or in combination. Virol J 2012, 27(9):74.
30. Arankalle V.A., Lole K.S., Deshmukh T.M., Srivastava S., Shaligram U.S. Challenge studies in Rhesus monkeys immunized with candidate hepatitis E vaccines: DNA, DNA-prime-protein-boost and DNA-protein encapsulated in liposomes. Vaccine 2009, 27:1032-1039.
31. Rakshit S., Ponnusamy M., Papanna S., Saha B., Ahmed A., Nandi D. Immunotherapeutic efficacy of Mycobacterium indicus pranii in eliciting anti-tumor T cell responses: critical roles of IFNγ. Int J Cancer 2012, 130:865-875.
32. Faujdar J., Gupta P., Natrajan M., Das R., Chauhan D.S., Katoch V.M., et al. Mycobacterium indicus pranii as stand-alone or adjunct immunotherapeutic in treatment of experimental animal tuberculosis. Indian J Med Res 2011, 134:696-703.
33. Adhikari A., Gupta G., Majumder S., Banerjee S., Bhattacharjee S., Bhattacharya P., et al. Mycobacterium indicus pranii (Mw) re-establishes host protective immune response in Leishmania donovani infected macrophages: critical role of IL-12. PLoS One 2012, 7:e40265.
34. Ahmad F., Mani J., Kumar P., Haridas S., Upadhyay P., Bhaskar S. Activation of anti-tumor immune response and reduction of regulatory T cells with Mycobacterium indicus pranii (MIP) therapy in tumor bearing mice. PLoS One 2011, 6:e25424.
35. De Becker G., Moulin V., Pajak B., Bruck C., Francotte M., Thiriart C., et al. The adjuvant monophosphoryl lipid A increases the function of antigen-presenting cells. Int Immunol 2000, 12:807-815.
36. Tiwari M., Parida M., Santhosh S.R., Khan M., Dash P.K., Rao P.V. Assessment of immunogenic potential of Vero adapted formalin inactivated vaccine derived from novel ECSA genotype of Chikungunya virus. Vaccine 2009, 27:2513-2522.